Biotech News
-
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX
October 29, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a Canadian public company…
-
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion
October 23, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF), (the “Company” or “Voyageur”) a Canadian developer…
-
Validated for Global Scale: DIAGNOS Passes Annual MDSAP Audit, Solidifying the Pathway to Approvals with Health Canada & FDA
October 8, 2025 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
DIAGNOS Announces Voting Results of Meeting of Shareholders
September 25, 2025 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
DIAGNOS Announces Private Placement
September 3, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform
August 25, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”) is pleased…
-
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
August 21, 2025 (Source) — TheNewswire – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a radiology…
-
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
August 19, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a company with…
-
Voyageur Advances Frances Creek Barite Project with VAST Engagement for Bulk Sample Permit
August 18, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”), is pleased to…
-
DIAGNOS to Extend Stock Warrants Exercise Period
August 15, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
